Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Hartmann

Showing results (541-550 of 626) with videos related to

Pageof 63
Sort By:
Journal of Medicinal Chemistry|October 16, 2008
Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1)Emmanuel Bey, Sandrine Marchais-Oberwinkler, Ruth Werth, et al.
Psychological Services|August 15, 2017
Adaptation of a nursing home culture change research instrument for frontline staff quality improvement useChristine W Hartmann, Jennifer A Palmer, Whitney L Mills, et al.
Journal of General Internal Medicine|February 9, 2021
Huddles and their effectiveness at the frontlines of clinical care: a scoping reviewCamilla B Pimentel, A Lynn Snow, Sarah L Carnes, et al.
Archiv Der Pharmazie|June 10, 2004
[1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action I: antitumor activity due to the reduction of the endogenous estrogen levelSabine Schertl, Rolf W Hartmann, Christine Batzl-Hartmann, et al.
Neuropathology and Applied Neurobiology|October 19, 2004
No evidence for mutations or altered expression of the Suppressor of Fused gene (SUFU) in primitive neuroectodermal tumoursA Koch, A Waha, W Hartmann, et al.
Journal of Medicinal Chemistry|July 18, 2008
Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokineticsSandrine Marchais-Oberwinkler, Patricia Kruchten, Martin Frotscher, et al.
Journal of Aging & Social Policy|April 4, 2023
Quality Improvement Efforts in VA Community Living Centers Following Public Reporting of PerformanceHeather Davila, Whitney L Mills, Valerie Clark, et al.
JMIR Research Protocols|July 21, 2021
Health Care Providers and the Public Reporting of Nursing Home Quality in the United States Department of Veterans Affairs: Protocol for a Mixed Methods Pilot StudyCamilla B Pimentel, Valerie Clark, Amy W Baughman, et al.
Journal of the American Chemical Society|August 19, 2017
Discovery of a Potent Inhibitor Class with High Selectivity toward Clostridial CollagenasesEsther Schönauer, Andreas M Kany, Jörg Haupenthal, et al.
Journal of Cancer Research and Clinical Oncology|October 7, 2006
Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studiesSabine Schertl, Rolf W Hartmann, Christine Batzl-Hartmann, et al.
Pageof 63

Showing results (541-550 of 626) with videos related to

Sort By:
Pageof 63
Journal of Medicinal Chemistry|October 16, 2008
Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1)Emmanuel Bey, Sandrine Marchais-Oberwinkler, Ruth Werth, et al.
Psychological Services|August 15, 2017
Adaptation of a nursing home culture change research instrument for frontline staff quality improvement useChristine W Hartmann, Jennifer A Palmer, Whitney L Mills, et al.
Journal of General Internal Medicine|February 9, 2021
Huddles and their effectiveness at the frontlines of clinical care: a scoping reviewCamilla B Pimentel, A Lynn Snow, Sarah L Carnes, et al.
Archiv Der Pharmazie|June 10, 2004
[1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action I: antitumor activity due to the reduction of the endogenous estrogen levelSabine Schertl, Rolf W Hartmann, Christine Batzl-Hartmann, et al.
Neuropathology and Applied Neurobiology|October 19, 2004
No evidence for mutations or altered expression of the Suppressor of Fused gene (SUFU) in primitive neuroectodermal tumoursA Koch, A Waha, W Hartmann, et al.
Journal of Medicinal Chemistry|July 18, 2008
Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokineticsSandrine Marchais-Oberwinkler, Patricia Kruchten, Martin Frotscher, et al.
Journal of Aging & Social Policy|April 4, 2023
Quality Improvement Efforts in VA Community Living Centers Following Public Reporting of PerformanceHeather Davila, Whitney L Mills, Valerie Clark, et al.
JMIR Research Protocols|July 21, 2021
Health Care Providers and the Public Reporting of Nursing Home Quality in the United States Department of Veterans Affairs: Protocol for a Mixed Methods Pilot StudyCamilla B Pimentel, Valerie Clark, Amy W Baughman, et al.
Journal of the American Chemical Society|August 19, 2017
Discovery of a Potent Inhibitor Class with High Selectivity toward Clostridial CollagenasesEsther Schönauer, Andreas M Kany, Jörg Haupenthal, et al.
Journal of Cancer Research and Clinical Oncology|October 7, 2006
Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studiesSabine Schertl, Rolf W Hartmann, Christine Batzl-Hartmann, et al.
Pageof 63